NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 241 filers reported holding NOVOCURE LTD in Q3 2019. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,458 | -63.6% | 1,824 | -6.5% | 0.00% | – |
| Q2 2023 | $80,925 | -12.5% | 1,950 | +26.9% | 0.00% | -100.0% |
| Q1 2023 | $92,435 | -20.3% | 1,537 | -2.8% | 0.00% | 0.0% |
| Q4 2022 | $116,040 | -5.7% | 1,582 | -2.2% | 0.00% | 0.0% |
| Q3 2022 | $123,000 | +9.8% | 1,618 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $112,000 | -30.4% | 1,613 | -17.0% | 0.00% | 0.0% |
| Q1 2022 | $161,000 | +10.3% | 1,944 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $146,000 | -37.6% | 1,943 | -3.3% | 0.00% | 0.0% |
| Q3 2021 | $234,000 | -51.2% | 2,010 | -7.1% | 0.00% | -50.0% |
| Q2 2021 | $480,000 | +60.5% | 2,163 | -4.2% | 0.00% | +100.0% |
| Q1 2021 | $299,000 | -31.7% | 2,259 | -10.7% | 0.00% | -50.0% |
| Q4 2020 | $438,000 | +51.6% | 2,530 | -2.7% | 0.00% | +100.0% |
| Q3 2020 | $289,000 | +79.5% | 2,600 | -4.4% | 0.00% | 0.0% |
| Q2 2020 | $161,000 | -95.4% | 2,719 | -94.7% | 0.00% | -94.7% |
| Q1 2020 | $3,463,000 | -24.5% | 51,428 | -5.5% | 0.02% | +5.6% |
| Q4 2019 | $4,584,000 | +11.8% | 54,400 | -0.8% | 0.02% | +5.9% |
| Q3 2019 | $4,102,000 | +20.4% | 54,857 | +1.8% | 0.02% | +30.8% |
| Q2 2019 | $3,407,000 | +50.7% | 53,883 | +14.8% | 0.01% | +44.4% |
| Q1 2019 | $2,261,000 | +39.4% | 46,930 | -3.1% | 0.01% | +28.6% |
| Q4 2018 | $1,622,000 | -36.6% | 48,452 | -0.8% | 0.01% | -12.5% |
| Q3 2018 | $2,558,000 | +74.6% | 48,825 | +4.3% | 0.01% | +60.0% |
| Q2 2018 | $1,465,000 | +79.5% | 46,807 | +25.1% | 0.01% | +66.7% |
| Q1 2018 | $816,000 | +3.8% | 37,429 | -3.8% | 0.00% | 0.0% |
| Q4 2017 | $786,000 | +2.2% | 38,906 | +0.5% | 0.00% | 0.0% |
| Q3 2017 | $769,000 | +24.0% | 38,722 | +8.1% | 0.00% | +50.0% |
| Q2 2017 | $620,000 | +145.1% | 35,826 | +14.9% | 0.00% | +100.0% |
| Q1 2017 | $253,000 | +10.5% | 31,191 | +7.1% | 0.00% | 0.0% |
| Q4 2016 | $229,000 | -99.9% | 29,126 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $249,385,000 | -26.7% | 29,202 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $340,274,000 | +379.3% | 29,158 | +496.3% | 0.00% | – |
| Q1 2016 | $71,000,000 | – | 4,890 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |